StreetInsider.com News Articles

AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test

Wed, 14 Oct 2026 09:45:00 -0400

News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.

BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies

AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test

Wed, 14 Oct 2026 09:45:00 -0400

News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.

AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test

Wed, 14 Oct 2026 09:45:00 -0400

News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.

AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test

Wed, 14 Oct 2026 09:45:00 -0400

News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.

AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test

Wed, 14 Oct 2026 09:45:00 -0400

News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.

AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test

Wed, 14 Oct 2026 09:45:00 -0400

News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.

AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test

Wed, 14 Oct 2026 09:45:00 -0400

News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.

AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test

Wed, 14 Oct 2026 09:45:00 -0400

News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.

AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test

Wed, 14 Oct 2026 09:45:00 -0400

News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.

AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test

Wed, 14 Oct 2026 09:45:00 -0400

News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.

Generate Biomedicines and Zealand Pharma strike AI drug deal

Tue, 13 Oct 2026 16:30:33 -0400

Generate Biomedicines Inc. (Nasdaq: GENB) and Zealand Pharma A/S (Nasdaq: ZEAL) announced a collaboration and license agreement to develop multispecific protein therapeutics for obesity and other metabolic diseases using Generate's generative AI platform.

Under the terms of the agreement, Generate will lead research through lead-candidate selection using its proprietary AI platform, while Zealand Pharma will take responsibility for clinical development, regulatory submissions, and worldwide commercialization.

Generate will receive $30 million upfront and up to $35 million in early preclinical milestones for two initial programs. The company is also eligible for total milestones of nearly $1.2 billion, including potential development, regulatory, and commercial

Generate Biomedicines and Zealand Pharma strike AI drug deal

Tue, 13 Oct 2026 16:30:33 -0400

Zealand Pharma and Generate Biomedicines strike AI drug deal

Tue, 13 Oct 2026 16:30:13 -0400

Zealand Pharma A/S (Nasdaq: ZEAL) and Generate Biomedicines Inc. (Nasdaq: GENB) announced a collaboration and license agreement on October 13, 2026, to develop multispecific protein therapeutics for obesity and other metabolic diseases using artificial intelligence.

Under the terms of the agreement, Generate will use its generative AI platform to lead research through lead-candidate selection for two initial programs, with an option to add a third. Zealand Pharma will take on responsibility for clinical development, regulatory submissions, and worldwide commercialization.

Generate will receive $30 million up-front and up to $35 million in early preclinical milestones. The company is also eligible for total milestones

Zealand Pharma and Generate Biomedicines strike AI drug deal

Tue, 13 Oct 2026 16:30:13 -0400

Generate will receive $30 million up-front and up to $35 million in early preclinical milestones. The company is also eligible for total milestones

Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Tue, 13 Oct 2026 16:30:00 -0400

Collaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functions

Generate will receive $30M upfront, up to $35M in early preclinical milestones, and a total of up to nearly $1.2B in milestones, plus tiered royalties for two initial programs, with an option to add a third

The agreement will broaden Zealand Pharma’s modality capabilities beyond peptides while extending The Generate Platform into obesity and other metabolic diseases

SOMERVILLE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc.

Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Tue, 13 Oct 2026 16:30:00 -0400

The agreement will broaden Zealand Pharma’s modality capabilities beyond peptides while extending The Generate Platform into obesity and other metabolic diseases

SOMERVILLE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc.

Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Tue, 13 Oct 2026 16:30:00 -0400

The agreement will broaden Zealand Pharma’s modality capabilities beyond peptides while extending The Generate Platform into obesity and other metabolic diseases

SOMERVILLE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc.

Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Tue, 13 Oct 2026 16:30:00 -0400

The agreement will broaden Zealand Pharma’s modality capabilities beyond peptides while extending The Generate Platform into obesity and other metabolic diseases

SOMERVILLE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc.

Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Tue, 13 Oct 2026 16:30:00 -0400

Press release – No. 20 / 2026

Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Collaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functions
Generate will receive USD 30 million up-front, up to USD 35 million in early preclinical milestones, and a total of nearly USD 1.2 billion in milestones, plus tiered royalties for two initial programs, with an option to add a third
The agreement

Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Tue, 13 Oct 2026 16:30:00 -0400

Press release – No. 20 / 2026

Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Collaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functions
Generate will receive USD 30 million up-front, up to USD 35 million in early preclinical milestones, and a total of nearly USD 1.2 billion in milestones, plus tiered royalties for two initial programs, with an option to add a third
The agreement

Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Tue, 13 Oct 2026 16:30:00 -0400

Press release – No. 20 / 2026

Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Collaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functions
Generate will receive USD 30 million up-front, up to USD 35 million in early preclinical milestones, and a total of nearly USD 1.2 billion in milestones, plus tiered royalties for two initial programs, with an option to add a third
The agreement

Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Tue, 13 Oct 2026 16:30:00 -0400

Press release – No. 20 / 2026

Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Collaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functions
Generate will receive USD 30 million up-front, up to USD 35 million in early preclinical milestones, and a total of nearly USD 1.2 billion in milestones, plus tiered royalties for two initial programs, with an option to add a third
The agreement

H.C. Wainwright Reiterates Buy Rating on Generate Biomedicines (GENB)

Mon, 05 Oct 2026 06:41:38 -0400

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating and $30.00 price target on Generate Biomedicines (NASDAQ: GENB).

The analyst commented: "Generate and Roswell Park announced first-patient dosing in the Phase 1 study of GB-5267, an autologous MUC16-directed, IL-18-armored CAR-T for platinum-resistant ovarian cancer. The study evaluates IV and intraperitoneal administration without lymphodepleting chemo. “Armored” CAR-Ts are engineered with functionality beyond the tumor-targeting CAR to help the cells operate in an immunosuppressive tumor microenvironment; GB-5267 secretes IL-18, intended to enhance CAR-T expansion/persistence and recruit endogenous immune cells. Other armoring strategies in development include secretion of cytokines such as IL-12/IL-18, resistance to

Roswell Park begins first human trial of AI-designed CAR T therapy

Thu, 01 Oct 2026 07:03:54 -0400

Roswell Park Comprehensive Cancer Center and Generate Biomedicines (NASDAQ: GENB) announced that the first patient has been dosed in a phase 1 clinical trial evaluating GB-5267, an investigational CAR T-cell therapy for ovarian cancer.

The trial, identified as NCT07489287, is evaluating the safety and tolerability of GB-5267 in patients whose ovarian cancer has returned after treatment or does not respond to platinum-based chemotherapy. It is led by principal investigator Emese Zsiros, MD, PhD, Chair of Gynecologic Oncology at Roswell Park.

GB-5267 is an autologous CAR T-cell therapy engineered with AI to target MUC16, an antigen expressed in more than 80% of ovarian

Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer

Thu, 01 Oct 2026 07:00:00 -0400

Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials

First patient treated in new clinical trial underway at Roswell Park

Treatment is designed to avoid pre-infusion chemotherapy and its side effects

GB-5267 targets MUC16, a biomarker over-expressed in +80% of ovarian tumors

BUFFALO, N.Y. and SOMERVILLE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Roswell Park Comprehensive Cancer Center (“Roswell Park”) and Generate Biomedicines, Inc. (“Generate”) today announced that the first patient has been dosed